
Richard N Fedorak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5004982/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An overview of clinical decision support systems: benefits, risks, and strategies for success. Npj Digital Medicine, 2020, 3, 17.	5.7	992
2	Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut, 2011, 60, 780-787.	6.1	750
3	The Probiotic VSL#3 Has Anti-inflammatory Effects and Could Reduce Endoscopic Recurrence After Surgery for Crohn's Disease. Clinical Gastroenterology and Hepatology, 2015, 13, 928-935.e2.	2.4	181
4	HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. Nature Genetics, 2014, 46, 1131-1134.	9.4	165
5	Probiotics and the Management of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2004, 10, 286-299.	0.9	155
6	Association of Genetic Variants in <i>NUDT15</i> With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	3.8	129
7	Probiotics and prebiotics in gastrointestinal disorders. Current Opinion in Gastroenterology, 2004, 20, 146-155.	1.0	108
8	Vitamin D improves inflammatory bowel disease outcomes: Basic science and clinical review. World Journal of Gastroenterology, 2014, 20, 4934.	1.4	95
9	Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Advanced Drug Delivery Reviews, 2005, 57, 303-316.	6.6	82
10	Trace Element Contamination of Total Parenteral Nutrition. 1. Contribution of Component Solutions. Journal of Parenteral and Enteral Nutrition, 1999, 23, 222-227.	1.3	81
11	Mucosal protective effects of vitamin E and misoprostol during acute radiation-induced enteritis in rats. Digestive Diseases and Sciences, 1992, 37, 205-214.	1.1	79
12	Stanniocalcin: a novel protein regulating calcium and phosphate transport across mammalian intestine. American Journal of Physiology - Renal Physiology, 1998, 274, G96-G102.	1.6	74
13	VSL#3 Probiotic Upregulates Intestinal Mucosal Alkaline Sphingomyelinase and Reduces Inflammation. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 237-242.	1.8	69
14	Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients na¬ve to anti-TNF therapy: An indirect treatment comparison meta-analysis. Journal of Crohn's and Colitis, 2014, 8, 571-581.	0.6	66
15	Distance management of inflammatory bowel disease: Systematic review and meta-analysis. World Journal of Gastroenterology, 2014, 20, 829.	1.4	64
16	Anti-TNF Therapy Within 2 Years of Crohn's Disease Diagnosis Improves Patient Outcomes. Inflammatory Bowel Diseases, 2016, 22, 870-879.	0.9	63
17	Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection. Open Forum Infectious Diseases, 2017, 4, ofw275.	0.4	62
18	Ulcerative Colitis Patients With Clostridium difficile are at Increased Risk of Death, Colectomy, and Postoperative Complications: A Population-Based Inception Cohort Study. American Journal of Gastroenterology, 2016, 111, 691-704.	0.2	56

#	Article	IF	CITATIONS
19	Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set. Clinical Gastroenterology and Hepatology, 2018, 16, 637-647.e13.	2.4	44
20	Crohn's disease outpatients treated with adalimumab have an earlier secondary loss of response and requirement for dose escalation compared to infliximab: A real life cohort study. Journal of Crohn's and Colitis, 2014, 8, 1454-1463.	0.6	43
21	Heterogeneity in Definitions of Efficacy and Safety EndpointsÂforÂClinical Trials of Crohn's Disease: AÂSystematicÂReview. Clinical Gastroenterology and Hepatology, 2018, 16, 1407-1419.e22.	2.4	41
22	Development and Validation of a Highly Sensitive Urine-Based Test to Identify Patients with Colonic Adenomatous Polyps. Clinical and Translational Gastroenterology, 2014, 5, e54.	1.3	36
23	Development of a core outcome set for clinical trials in inflammatory bowel disease: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. BMJ Open, 2017, 7, e016146.	0.8	35
24	Preoperative Ustekinumab Treatment Is Not Associated With Increased Postoperative Complications in Crohn's Disease: A Canadian Multi-Centre Observational Cohort Study. Journal of the Canadian Association of Gastroenterology, 2018, 1, 115-123.	0.1	34
25	Incidence Rates for Surgery in Crohn's Disease Have Decreased: A Population-based Time-trend Analysis. Inflammatory Bowel Diseases, 2020, 26, 1909-1916.	0.9	34
26	Canadian Digestive Health Foundation Public Impact Series: Gastroesophageal Reflux Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 431-434.	1.8	31
27	Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study. World Journal of Gastroenterology, 2017, 23, 3890.	1.4	28
28	Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis. Frontiers in Immunology, 2018, 9, 2211.	2.2	22
29	Canadian Digestive Health Foundation Public Impact Series. Inflammatory Bowel Disease in Canada: Incidence, Prevalence, and Direct and Indirect Economic Impact. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 651-655.	1.8	21
30	Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-9.	0.8	20
31	A Randomized Trial of Topical Anesthesia Comparing Lidocaine Versus Lidocaine Plus Xylometazoline for Unsedated Transnasal Upper Gastrointestinal Endoscopy. Canadian Journal of Gastroenterology & Hepatology, 2010, 24, 317-321.	1.8	16
32	Canadian Digestive Health Foundation Public Impact Series 3: Irritable Bowel Syndrome in Canada. Incidence, Prevalence, and Direct and Indirect Economic Impact. Canadian Journal of Gastroenterology & Hepatology, 2012, 26, 252-256.	1.8	14
33	Early Initiation of Tumor Necrosis Factor Antagonist–Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation. Clinical Gastroenterology and Hepatology, 2019, 17, 1515-1524.e4.	2.4	14
34	Increased permeability occurs in rat ileum following induction of pancolitis. Digestive Diseases and Sciences, 1996, 41, 405-411.	1.1	13
35	Clinical Aspects of Trace Elements: Zinc in Human Nutrition - Assessment of Zinc Status. Canadian Journal of Gastroenterology & Hepatology, 1996, 10, 37-42.	1.8	11
36	Is it time to re-classify Crohn's disease?. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 99-106.	1.0	11

RICHARD N FEDORAK

#	Article	IF	CITATIONS
37	Real-life Treatment Paradigms Show Infliximab Is Cost-effective forÂManagement of Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2014, 12, 1871-1878.e8.	2.4	11
38	Acetic acid-induced colitis results in bystander ileal injury. Agents and Actions, 1993, 38, 76-84.	0.7	10
39	Antigenic Mimicry BetweenHelicobacter pyloriand Gastric Mucosa: Failure to Implicate Heatâ€Shock Protein Hsp60 Using Immunoelectron Microscopy. Helicobacter, 1999, 4, 148-153.	1.6	10
40	Epithelial Cell Extrusion Zones Observed on Confocal Laser Endomicroscopy Correlates with Immunohistochemical Staining of Mucosal Biopsy Samples. Digestive Diseases and Sciences, 2016, 61, 1895-1902.	1.1	9
41	Steady-state pharmacokinetics of corticosteroid delivery from glucuronide prodrugs in normal and colitic rats. , 1997, 18, 681-695.		8
42	IBDoc Canadian User Performance Evaluation. Inflammatory Bowel Diseases, 2019, 25, 1107-1114.	0.9	8
43	Management of Inflammatory Bowel Disease Patients With Clinical Care Pathways Reduces Emergency Department Utilization. Crohn's & Colitis 360, 2020, 2, .	0.5	8
44	Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. Digestive Diseases, 2016, 34, 112-121.	0.8	7
45	Effect ofLactobacillus plantarum299v treatment in an animal model of irritable bowel syndrome. Microbial Ecology in Health and Disease, 2009, 21, 33-37.	3.8	6
46	Real-Life Treatment Paradigms Show Adalimumab Is Cost-Effective for the Management of Ulcerative Colitis. Canadian Journal of Gastroenterology and Hepatology, 2016, 2016, 1-11.	0.8	6
47	Urine-based metabolomic analysis of patients with Clostridium difficile infection: a pilot study. Metabolomics, 2016, 12, 1.	1.4	6
48	Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. Frontiers in Medicine, 2019, 6, 170.	1.2	6
49	Vanadate reduces sodium-dependent glucose transport and increases glycolytic activity in LLC-PK1 epithelia. Journal of Cellular Physiology, 1994, 158, 459-466.	2.0	4
50	Recurrent Fevers After Infliximab Therapy for Ulcerative Colitis. Gastroenterology, 2016, 150, e1-e2.	0.6	4
51	A Profile of Patients on ASA or NSAIDs Hospitalized with Gastrointestinal Perforations. Canadian Journal of Gastroenterology & Hepatology, 1995, 9, 387-392.	1.8	1
52	Short Bowel Syndrome. , 0, , 340-357.		1
53	Glutamine and Its Effects on the Intestine. Canadian Journal of Gastroenterology & Hepatology, 1991, 5, 94-102.	1.8	0
54	Clinical Aspects of Trace Elements: Zinc in Human Nutrition – Zinc Requirements. Canadian Journal of Gastroenterology & Hepatology, 1995, 9, 368-372.	1.8	0

0

#	Article	IF	CITATIONS
55	Osteoporosis of Crohn's Disease: A Critical Review. Canadian Journal of Gastroenterology & Hepatology, 1996, 10, 317-321.	1.8	0

56 Short Bowel Syndrome. , 0, , 1295-1321.